Skip to main content

Sustainable Influenza Vaccine Production Capacity Stakeholders' Workshop: Day 1 Videos

January 11, 2010 - Washington, D.C.
VideosVideos: DAY 1 | DAY 2 | DAY 3

Opening Remarks by Dr. Nicole Lurie
Introductions and Keynote Address

Welcome, Introduction to the Objectives of the Meeting, and Keynote address: Global Response to the H1N1 Pandemic Deployment of Vaccine in Developing Countries by Dr. Marie-Paule Kieny
Overview of Current Vaccine Manufacturing Capacity in Developing Countries: Existing Infrastructure

Presentations and discussion session.
  • Pandemic A(H1N1) 2009 Vaccine Production: Preliminary 2010 Survey Results by Dr. Marie-Paule Kieny
  • Overview of Current Vaccine Manufacturing Capacity in Developing Countries: Existing Infrastructure: Current Status at SIIL/Pune for Pandemic Influenza Vaccine by Dr. Suresh Jadhav
Existing Efforts to Develop Sustainable Vaccine Manufacturing Capacity in Developing Countries

Presentations and discussion session.
  • Commitment to the Creation of Sustainable Influenza Vaccine Production Capacity Worldwide by Ms. Christina M. Hartman
  • Development of International Influenza Vaccine Production Capacity: Update of WHO Programme by Dr. Laszlo Palkonyay
  • Progress in Influenza Vaccine Capacity Building in Vietnam by Dr. Rick Bright
Role of New and Existing Technologies and Adjuvants and Technology Transfer Models

Presentations and discussion session.
  • Roles of Existing Technologies and Adjuvants by Dr. Robin Robinson
  • Cell-Based and Recombinant Influenza Vaccine Manufacturing Technologies for Pandemic Influenza Preparedness by Dr. Armen Donabedian
  • Gates Foundation Influenza Vaccine Program by Dr. Douglas Holtzman
  • Examples of Vaccine Know-How Transfer by Dr. Jan Hendriks
Defining Manufacturing Standards, Regulatory Needs, and Capacity and Role of Clinical Trials

Presentations and discussion session.
  • Technical Considerations: Defining Manufacturing Standards Regulatory Needs, and Capacity and Role of Clinical Trials by Dr. David Wood
  • PATH's Experiences in Vietnam on Vaccine Clinical Trials by Dr. Vu Minh Huong
Ensuring the Best Returns on Investment while Ensuring Sustainability and Diversification

Presentations and discussion session.
  • Sustainable Influenza Vaccine Production Capacity Cost Considerations: Ensuring the Best Returns on Investment while Ensuring Sustainability and Diversification by Dr. Barry Bloom
  • Flu Vaccine Production by the Thai GPO: Economic Return VS National Security Concept - Balancing Sustainability and Cost-Effectiveness by Dr. Vichai Chokevivat
Discussion and Final Comments from Day 1